Table 4.

Percentage Change in HDL Function Marker by Covariate in Multivariate Repeated Measures Analysis-ESR Models.

	HII		PON1 Activity		HDL-Hp		HDL-ApoAI		MPO
	Effects	p	Effects	P	Effects	p	Effects	p	Effects	P
ESR (per 10 unit decrease)	−2.88%	<0.001	1.72%	0.13	−4.14%	<.0001	9.08%	<0.001	−1.61%	0.09
Treatment (overall)		0.02		0.74		0.11		0.24		0.45
MTX + ETA vs TT	10.61%	0.05	3.31%	0.65	9.54%	0.04	−20.15%	0.18	−4.23%	0.42
MTX + ETA vs MTX	−3.97%	0.33	−2.57%	0.68	1.31%	0.74	6.54%	0.65	3.36%	0.52
TT vs MTX	−13.18%	0.01	−5.69%	0.44	−7.51%	0.10	33.42%	0.10	7.93%	0.21
Race (overall)		0.03		<0.01		0.04		0.08		<0.001
AA vs Caucasian	−20.26%	0.02	47.05%	<0.01	−14.96%	0.03	85.02%	0.04	38.35%	<0.001
AA vs Others	−26.43%	0.02	19.03%	0.28	−21.05%	0.02	132.84%	0.04	17.18%	0.17
Others vs Caucasian	8.39%	0.39	23.54%	0.08	7.73%	0.31	−20.54%	0.44	18.07%	0.06
BMI (per unit increase)	1.16%	0.00	−0.42%	0.37	0.70%	0.02	−2.78%	0.02	−0.24%	0.50
Age (per year increase)	−0.05%	0.82	0.26%	0.38	−0.14%	0.43	1.10%	0.14	−0.25%	0.24
Female vs Male	−9.00%	0.12	9.72%	0.24	−4.13%	0.38	15.18%	0.48	−16.01%	<0.01
Disease Duration (per year increase)	0.52%	0.21	0.04%	0.94	0.70%	0.75	0.19%	0.89	−1.03%	<0.01
Baseline Smoking: Yes vs No	11.47%	0.06	1.18%	0.87	0.14%	0.94	−32.04%	0.04	4.72%	0.39
Baseline Prednisone Use: Yes vs No	−2.68%	0.61	10.88%	0.13	6.85%	0.11	37.53%	0.07	7.32%	0.16
Baseline Statin Use: Yes vs No	−13.62%	0.09	−4.38%	0.68	5.60%	0.42	39.74%	0.23	−7.77%	0.31
Baseline Cardiovascular Disease: Yes vs No	10.73%	0.44	−19.92%	0.19	−15.38%	0.11	9.48%	0.83	−7.97%	0.50
Baseline Diabetes Status: Yes vs No	−14.29%	0.10	−2.68%	0.82	−11.90%	0.09	−6.62%	0.83	0.52%	0.95

Percentage change in HDL function variables are shown per categorical variable or per unit change in continuous variables as specified. CRP= C-reactive protein. TT= triple therapy. MTX= methotrexate. ETA= etanercept. AA = African American. BMI= body mass index.